Business
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
Online preprint details full Phase 1 data set of 120 participants, of which 82.5% received a booster dose of INO-4800 INO-4800 was well-tolerated, with no
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Online preprint details full Phase 1 data set of 120 participants, of which 82.5% received a booster dose of INO-4800\n INO-4800 was well-tolerated, with no serious adverse events reported\n Booster dose significantly increased the immune responses that resulted from the second dose\n\n\nPLYMOUTH MEETING, Pa., Oct. 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800. \nThe paper, titled \"SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial,\" found that among the full Phase 1 cohort of 120 participants – of which 82.5%, or 99 participants, received a booster (or third) dose – INO-4800 produced robust immune responses and was well-tolerated as both a two-dose series and as a homologous booster dose in all adults, including participants 65 years of age and older. Of note, a durable antibody response was observed six months following the second dose, and a homologous booster dose administered 6 to 10.5 months following the second dose also significantly increased antibody and T cell responses. INO-4800 was well-tolerated, with no treatment-related serious adverse events reported. Most adverse events were mild in severity and did not increase in frequency with age and subsequent dosing.\nDr. J. Joseph Kim, President and CEO of INOVIO, said, \"We are pleased to share the clinical data on the homologous boosting of INO-4800, as well as for our full Phase 1 cohort. As much of the world's population remains unvaccinated and susceptible to COVID-19, there remains an urgent need for additional safe and effective vaccines that are affordable, scalable and can be distributed to countries where the infrastructure may not be supportive of ultra-cold chain transport and storage. We believe that INO-4800, if approved, will be well suited to support the continued fight against COVID-19 – both as a primary vaccination and as a booster. We look forward to contributing to the international public health knowledge base via our global Phase 3 clinical trial.\"\nT...